Trial · NCT04767373
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| RSV Season 1: Number of Participants With Respiratory Syncytial Virus (RSV)-Associated Medically Attended Lower Respiratory Infection (MALRI) | RSV Season 1: Clesrovimab 105 mg | 60 | Participants | ||
| RSV Season 1: Number of Participants With Respiratory Syncytial Virus (RSV)-Associated Medically Attended Lower Respiratory Infection (MALRI) | RSV Season 1: Placebo | 74 | Participants | ||
| RSV Season 1: Percentage of Participants With Solicited Injection-Site Adverse Events (AEs) | RSV Season 1: Clesrovimab 105 mg | 11.4 | Percentage of participants | ||
| RSV Season 1: Percentage of Participants With Solicited Injection-Site Adverse Events (AEs) | RSV Season 1: Placebo | 11.7 | Percentage of participants | ||
| RSV Season 1: Percentage of Participants With Fever | RSV Season 1: Clesrovimab 105 mg | 0.5 | Percentage of participants | ||
| RSV Season 1: Percentage of Participants With Fever | RSV Season 1: Placebo | 1.2 | Percentage of participants | ||
| RSV Season 1: Percentage of Participants With Solicited Systemic AEs | RSV Season 1: Clesrovimab 105 mg | 30.1 | Percentage of participants | ||
| RSV Season 1: Percentage of Participants With Solicited Systemic AEs | RSV Season 1: Placebo | 31.2 | Percentage of participants | ||
| RSV Season 1: Percentage of Participants With Anaphylaxis/Hypersensitivity AE of Special Interest (AESI) | RSV Season 1: Clesrovimab 105 mg | 0.0 | Percentage of participants | ||
| RSV Season 1: Percentage of Participants With Anaphylaxis/Hypersensitivity AE of Special Interest (AESI) | RSV Season 1: Placebo | 0.0 | Percentage of participants | ||
| RSV Season 1: Percentage of Participants With Rash AESI | RSV Season 1: Clesrovimab 105 mg | 0.5 | Percentage of participants | ||
| RSV Season 1: Percentage of Participants With Rash AESI | RSV Season 1: Placebo | 0.3 | Percentage of participants | ||
| RSV Season 1: Percentage of Participants With ≥1 Nonserious AE | RSV Season 1: Clesrovimab 105 mg | 74.8 | Percentage of participants | ||
| RSV Season 1: Percentage of Participants With ≥1 Nonserious AE | RSV Season 1: Placebo | 75.5 | Percentage of participants | ||
| Percentage of Participants With Serious Adverse Events (SAEs) | RSV Season 1: Clesrovimab 105 mg | 11.7 | Percentage of participants | ||
| Percentage of Participants With Serious Adverse Events (SAEs) | RSV Season 1: Placebo | 12.6 | Percentage of participants | ||
| Percentage of Participants With Serious Adverse Events (SAEs) | RSV Season 2: Clesrovimab 105 mg | 3.1 | Percentage of participants | ||
| Percentage of Participants With Serious Adverse Events (SAEs) | RSV Season 2: Placebo | 4.0 | Percentage of participants | ||
| RSV Season 1: Number of Participants With RSV-Associated Hospitalization | RSV Season 1: Clesrovimab 105 mg | 9 | Participants | ||
| RSV Season 1: Number of Participants With RSV-Associated Hospitalization | RSV Season 1: Placebo | 28 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04767373/results